These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 25323007

  • 1. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
    Wang J, Zhang Y, Liu X, Ma J, Liu P, Hu C, Zhang G.
    Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
    [Abstract] [Full Text] [Related]

  • 2. Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
    Wu L, Yang L, Xiong Y, Guo H, Shen X, Cheng Z, Zhang Y, Gao Z, Zhu X.
    Tumour Biol; 2014 Dec; 35(12):12327-37. PubMed ID: 25245332
    [Abstract] [Full Text] [Related]

  • 3. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J, Ge X, Zhang W, Ding P, Du Y, Wang Q, Li L, Fang L, Sun Y, Zhang P, Zhou Y, Zhang L, Lv X, Li L, Zhang X, Zhang Q, Xue K, Gu H, Lei Q, Wong J, Hu W.
    Theranostics; 2020 Dec; 10(7):3151-3163. PubMed ID: 32194860
    [Abstract] [Full Text] [Related]

  • 4. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.
    Maxwell SA, Cherry EM, Bayless KJ.
    Leuk Lymphoma; 2011 May; 52(5):849-64. PubMed ID: 21323512
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.
    Bai H, Wei J, Deng C, Yang X, Wang C, Xu R.
    Int J Hematol; 2013 Feb; 97(2):223-31. PubMed ID: 23275230
    [Abstract] [Full Text] [Related]

  • 6. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
    Ageberg M, Rydström K, Lindén O, Linderoth J, Jerkeman M, Drott K.
    Exp Cell Res; 2011 May 01; 317(8):1179-91. PubMed ID: 21324313
    [Abstract] [Full Text] [Related]

  • 9. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 01; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
    Ma Y, Zhang P, Gao Y, Fan H, Zhang M, Wu J.
    Int J Clin Exp Pathol; 2015 Dec 01; 8(11):14875-84. PubMed ID: 26823817
    [Abstract] [Full Text] [Related]

  • 13. Marine sponge-derived alkaloid inhibits the PI3K/AKT/mTOR signaling pathway against diffuse large B-cell lymphoma.
    Liu J, Chang YT, Kou YY, Zhang PP, Dong QL, Guo RY, Liu LY, Lin HW, Yang F.
    Med Oncol; 2024 Jul 29; 41(9):212. PubMed ID: 39073639
    [Abstract] [Full Text] [Related]

  • 14. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N, Wang CY, Sun YQ, Ruan YJ, Huang YY, Su T, Zhou XH, Huang H, Guo WJ, He MQ, Yao RX, Lin XJ.
    Biomed Pharmacother; 2018 Oct 29; 106():267-274. PubMed ID: 29966970
    [Abstract] [Full Text] [Related]

  • 15. High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma.
    Tang J, Qin Z, Han P, Wang W, Yang C, Xu Z, Li R, Liu B, Qin C, Wang Z, Tang M, Zhang W.
    Int J Oncol; 2017 May 29; 50(5):1839-1847. PubMed ID: 28393205
    [Abstract] [Full Text] [Related]

  • 16. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF.
    Hum Pathol; 2014 Aug 29; 45(8):1664-73. PubMed ID: 24931464
    [Abstract] [Full Text] [Related]

  • 17. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
    Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H.
    J Biol Chem; 2009 Aug 14; 284(33):22379-22389. PubMed ID: 19525224
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW, Steidl C, Sehn LH, Gascoyne RD.
    Br J Haematol; 2014 Dec 14; 167(5):608-17. PubMed ID: 25135752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.